A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Active, not recruiting · NCT06003231 · Registry updated 2026-07-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, uterine disorder | Active, not recruiting | Phase 2 | 2026-07-22 | NCT06003231 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Seagen, a wholly owned subsidiary of Pfizer | 16 |
96 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.